SEC 13F Intelligence

Managers / Q2 2020 · view latest →

HighVista Strategies LLC

CIK 0001335325 · 200 CLARENDON STREET, 50TH FLOOR, BOSTON, MA, 02116 · 617-406-6500

Reported Value
$121M
Q2 2020
Positions
100
Filings on Record
30
2019–present window
Filed
Aug 14, 2020
original filing

Summary

Highvista Strategies LLC reported $121M in U.S.-listed holdings across 100 positions for Q2 2020.

The portfolio is heavily concentrated: DELL alone accounts for 31.0% of reported value.

Compared with Q1 2020, the fund opened 60 new positions and exited 25.

Portfolio Metrics

Turnover
+39.8%
vs prior filed quarter
Top-10 Concentration
+72.0%
share of reported value
Largest Position
+31.0%
Dell Technologies
New / Exited
60 / 25
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $116MQ4 ’18Q1 ’19: $123MQ2 ’19: $195MQ3 ’19: $147MQ4 ’19: $132MQ4 ’19Q1 ’20: $108MQ2 ’20: $121MQ3 ’20: $137MQ4 ’20: $157MQ4 ’20Q1 ’21: $135MQ2 ’21: $141MQ3 ’21: $151MQ4 ’21: $126MQ4 ’21Q1 ’22: $157MQ2 ’22: $166MQ3 ’22: $175MQ4 ’22: $168MQ4 ’22Q1 ’23: $123MQ2 ’23: $219MQ3 ’23: $216MQ4 ’23: $276MQ4 ’23Q1 ’24: $280MQ2 ’24: $274MQ3 ’24: $290MQ4 ’24: $269MQ4 ’24Q1 ’25: $260MQ2 ’25: $272MQ3 ’25: $408MQ4 ’25: $388MQ4 ’25Q1 ’26: $362Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 78.0%Other: 11.3%ADR: 8.0%ETP: 2.6%REIT: 0.1%
  • Common Stock · 78.0% · $94M
  • Other · 11.3% · $14M
  • ADR · 8.0% · $10M
  • ETP · 2.6% · $3M
  • REIT · 0.1% · $112,000

Quarter-over-Quarter Changes full breakdown →

vs Q1 2020 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
CZREURCAESARS ENTMT CORPNEW+342.4K342.4K+$4M$4M
WRIGHT MED GROUP N VNEW+98.0K98.0K+$3M$3M
LOGMEURLOGMEIN INCNEW+34.1K34.1K+$3M$3M
AXSMAXSOME THERAPEUTICS INCNEW+6.9K6.9K+$571,000$571,000
CCXIEURCHEMOCENTRYX INCNEW+9.8K9.8K+$562,000$562,000
PRNBPRINCIPIA BIOPHARMA INCNEW+9.2K9.2K+$548,000$548,000
ADVMCHFADVERUM BIOTECHNOLOGIES INCNEW+26.2K26.2K+$547,000$547,000
DRNAUSDDICERNA PHARMACEUTICALS INCNEW+21.2K21.2K+$538,000$538,000

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2020

49 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1DELLDELL TECHNOLOGIES INChistory →CL C30.97%$37M680.6K
2WILLIS TOWERS WATSON PLC LTDSHS6.70%$8M41.1K
3TECD1USDTECH DATA CORPhistory →COM6.55%$8M54.6K
4BABAALIBABA GROUP HLDG LTDhistory →SPONSORED ADS6.43%$8M36.0K
5AMTTD AMERITRADE HLDG CORPhistory →COM5.50%$7M182.6K
6TIFEURTIFFANY & CO NEWhistory →COM5.16%$6M51.1K
7CZREURCAESARS ENTMT CORPhistory →COM3.44%$4M342.4K
8ACIAACACIA COMMUNICATIONS INChistory →COM2.47%$3M44.4K
9FITEURFITBIT INChistory →CL A2.41%$3M451.0K
10WRIGHT MED GROUP N VORD SHS2.41%$3M98.0K
11LOGMEURLOGMEIN INChistory →COM2.39%$3M34.1K
12ISHARES TRMSCI INDIA ETF · MSCI INDIA SM CP2.17%$3M90.2K
13GNWGENWORTH FINL INChistory →COM CL A1.11%$1M578.0K
14AXSMAXSOME THERAPEUTICS INCCOM0.47%$571,0006.9K
15CCXIEURCHEMOCENTRYX INCCOM0.47%$562,0009.8K
16PRNBPRINCIPIA BIOPHARMA INCCOM0.45%$548,0009.2K
17ADVMCHFADVERUM BIOTECHNOLOGIES INCCOM0.45%$547,00026.2K
18DRNAUSDDICERNA PHARMACEUTICALS INCCOM0.45%$538,00021.2K
19RCKTROCKET PHARMACEUTICALS INCCOM0.43%$524,00025.0K
20DBCINVESCO DB COMMDY INDX TRCKUNIT0.43%$522,00042.4K
21TGTXTG THERAPEUTICS INCCOM0.42%$512,00026.3K
22EIDXGBPEIDOS THERAPEUTICS INCCOM0.42%$505,00010.6K
23TSMTAIWAN SEMICONDUCTOR MFG LTDSPONSORED ADS0.42%$505,0008.9K
24ARVNARVINAS INCCOM0.40%$485,00014.5K
25NVONOVO-NORDISK A SADR0.40%$485,0007.4K
26KURAKURA ONCOLOGY INCCOM0.40%$485,00029.7K
27KODKODIAK SCIENCES INCCOM0.40%$479,0008.8K
28NEOLEUKIN THERAPEUTICS INCCOM0.39%$474,00028.6K
29DCPHEURDECIPHERA PHARMACEUTICALS INCOM0.38%$461,0007.7K
30CRNXCRINETICS PHARMACEUTICALS INCOM0.37%$450,00025.7K
31TREURTRILLIUM THERAPEUTICS INCCOM NEW0.37%$449,00055.6K
321K0IGM BIOSCIENCES INCCOM0.37%$449,0006.1K
33SWTXUSDSPRINGWORKS THERAPEUTICS INCCOM0.37%$447,00010.6K
34CNSTCONSTELLATION PHARMCETICLS ICOM0.37%$447,00014.9K
351T7TRICIDA INCCOM0.37%$446,00016.2K
36IM8NINSMED INCCOM PAR $.010.36%$438,00015.9K
37RLMDRELMADA THERAPEUTICS INCCOM0.36%$434,0009.7K
38CDXSCODEXIS INCCOM0.36%$433,00038.0K
39KDMNKADMON HLDGS INCCOM0.36%$433,00084.6K
40SGENUSDSEATTLE GENETICS INCCOM0.36%$433,0002.5K
41ASCENDIS PHARMA A SSPONSORED ADR0.35%$428,0002.9K
42FATEFATE THERAPEUTICS INCCOM0.35%$428,00012.5K
43ACADACADIA PHARMACEUTICALS INCCOM0.35%$426,0008.8K
44IOVAIOVANCE BIOTHERAPEUTICS INCCOM0.35%$425,00015.5K
45VERASTEM INCCOM0.35%$425,000247.1K
46ALECALECTOR INCCOM0.35%$424,00017.4K
47STOKSTOKE THERAPEUTICS INCCOM0.35%$423,00017.7K
48ARGXARGENX SESPONSORED ADR0.35%$422,0001.9K
492655787DBLUEPRINT MEDICINES CORPCOM0.35%$421,0005.4K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$362M156May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$388M145Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$408M148Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$272M146Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$260M148May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$269M137Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$290M142Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$274M138Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$280M131May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$276M126Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$216M132Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$219M134Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$123M108May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$168M105Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$175M113Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$166M110Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$157M86May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$126M69Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$151M127Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$141M116Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$135M125May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$157M117Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$137M113Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$121M100Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$108M65May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$132M119Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$147M126Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$195M108Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$123M112May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$116M113Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.